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Abstract
Osteoporosis is a common clinical problem, especially in patients
with rheumatoid arthritis (RA). A reduction in bone mineral density
(BMD) of the axial and appendicular skeleton ranging from 7% to
15% has been reported in RA in studies employing a variety of
densitometric techniques. Reports consistent with a beneficial
effect of tumour necrosis factor blockade on BMD have begun to
emerge in recent years, and in Arthritis Research and Therapy, a
case control study reports that patients treated with infliximab for
RA had preservation of BMD in the lumbar spine and femoral neck
compared to those treated with methotrexate.
Generalised osteoporosis is just one of three bony manifes-
tations of rheumatoid arthritis (RA), which also include
erosions and localised juxta-articular bone loss of affected
joints. Although a number of causes for this generalised
osteoporosis have been proposed [1,2], increasing evidence
suggests a common mechanism for all three bone
manifestations. Control of inflammation appears to be the
most important strategy for prevention of bone loss in RA [3].
The discovery of the receptor activator of nuclear factor κB
(RANK) ligand (RANKL) pathway, a transmembrane protein
belonging to the tumour necrosis factor (TNF) superfamily,
and its inhibition by osteoprotogerin (OPG) has had
important implications for bone physiology as well as
inflammation research. RANK and its decoy receptor OPG
are key regulators of osteoclastic bone resorption in vitro and
in vivo [4,5]. Osteoblasts express RANKL constitutively on
their cell surface. This interacts with its cognate receptor
RANK, which is expressed on osteoclast precursors and
promotes osteoclast differentiation. Interaction of RANKL
with RANK on mature osteoclasts results in their activation
and prolonged survival. OPG is secreted primarily by
osteoblasts and stromal cells. OPG blocks the interaction of
RANKL with RANK and thus acts as a physiological regulator
of bone turnover. These observations suggest that TNF
blockade may have a beneficial effect on bone generally, not
just on erosions in RA.
In the previous issue of Arthritis Research and Therapy,
Marotte and colleagues [6] reported a case control study in
99 patients with RA treated with infliximab. After 12 months,
patients receiving infliximab had preservation of bone mineral
density (BMD) in the lumbar spine and femoral neck whereas
bone loss amounting to 3.9% and 2.5% was observed at the
same sites, respectively, in the control group treated with
methotrexate alone. Changes in biochemical markers of bone
turnover from baseline or between the groups were not
statistically different. However, the trends in both serum
osteocalcin (a formation marker) and serum carboxy-terminal
telopeptide of type I collagen (CTX; a resorption marker)
suggest that a greater decrease in remodelling activity
occurred with infliximab. Of particular interest, the benefit on
BMD with infliximab treatment appeared to occur
independently of the clinical response in terms of effect on
RA activity. Reports consistent with effects of TNF blockade
on BMD have begun to emerge in recent years [7-9].
Earlier smaller studies also suggested a beneficial effect of
TNF blockade on osteoporosis in RA. Lange and colleagues
[7] studied 26 patients with RA treated with infliximab and
observed an increase in spine and femoral neck BMD of
2.7% and 13%, respectively. Serum osteocalcin levels rose
whilst a resorption marker (serum crosslaps) fell, but there
was no control group. Vis and colleagues [8] also reported
stable spine and hip BMD as opposed to an expected
decline in 102 RA patients treated with infliximab. Serum
CTX levels decreased significantly with infliximab therapy.
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Seriolo and colleagues [9] studied 30 RA patients treated
with TNF blockers, 11 of whom were treated with etanercept
and 10 with infliximab. BMD trends favoured TNF blockade
but were small and non-significant. Serum osteocalcin rose
and the resorption marker urinary deoxypyrdinoline decreased.
Most of these reports have been with infliximab. It is unclear
whether a similar trend occurs with other TNF blockers such
as etanercept.
A few very early studies have also examined the effect of
disease modifying drugs on bone loss in RA using older
densitometric techniques like metacarpal morphometry. In a
study of 70 patients, Schorn and Mowat [10] reported meta-
carpal cortical width improved with D-penicillamine after one
year. In a subsequent study of 113 patients, Schorn [11]
reported D-penicillamine but not oral gold reversed bone loss
over 12 months. In a study of 81 patients over 18 months,
Kalla and colleagues [12] reported significant effects on
metacarpal cortical width with sulphasalazine, antimalarials
and injectable gold. Of interest, the manual technique of
metacarpal morphometry employed in these three old studies
is identical with that measured by modern day automated
radiogrammetry. Moreoever, automated radiogrammetry using
hand X-rays shows a strong correlation with BMD assessed
by dual energy X-ray absorptiometry [13].
In summary, studies like that by Marotte and colleagues [6]
suggest TNF blockade may have a role in prevention of
generalised osteoporosis in both rheumatic diseases and
postmenopausal osteoporosis. However, properly controlled
trials are needed to fully evaluate the effect of TNF blockers in
this regard. An interesting observation here is that the
availability of automated radiogrammetry means that the
effect of TNF blockers on BMD could be easily assessed.
Modern clinical trials with TNF blockers in RA have included
hand X-rays to assess efficacy. Application of such auto-
mated radiogrammetry to the existing clinical trial data (such
as these hand X-rays) offers an opportunity to examine the
effects of TNF blockade on bone loss and hence osteo-
porosis. It would also be an example of how older metho-
dology can still provide insights into modern aspects of patho-
genesis and treatment – hence the title ‘back to the future’.
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